STAAR Surgical (NASDAQ:STAA – Get Free Report) had its price objective boosted by analysts at Mizuho from $22.00 to $27.00 in a research report issued to clients and investors on Thursday, Marketbeat Ratings reports. The brokerage presently has a “neutral” rating on the medical instruments supplier’s stock. Mizuho’s price target would indicate a potential downside of 15.81% from the stock’s previous close.
A number of other research firms have also commented on STAA. Wedbush raised their price target on STAAR Surgical from $21.00 to $26.00 and gave the stock a “neutral” rating in a research report on Thursday, April 9th. Wall Street Zen raised STAAR Surgical to a “hold” rating in a research report on Saturday, April 11th. Piper Sandler raised their price target on STAAR Surgical from $16.00 to $33.00 and gave the stock a “neutral” rating in a research report on Thursday. Weiss Ratings lowered STAAR Surgical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 22nd. Finally, Canaccord Genuity Group raised STAAR Surgical from a “hold” rating to a “buy” rating and raised their price target for the stock from $22.00 to $27.00 in a research report on Thursday, April 9th. Three research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, STAAR Surgical presently has an average rating of “Hold” and a consensus target price of $27.81.
View Our Latest Research Report on STAAR Surgical
STAAR Surgical Trading Up 0.2%
STAAR Surgical (NASDAQ:STAA – Get Free Report) last released its earnings results on Wednesday, May 13th. The medical instruments supplier reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.05. STAAR Surgical had a positive return on equity of 3.31% and a negative net margin of 7.24%.The firm had revenue of $93.52 million for the quarter, compared to analyst estimates of $78.72 million. During the same quarter in the prior year, the firm posted ($1.10) earnings per share. The company’s quarterly revenue was up 119.6% on a year-over-year basis. On average, equities analysts expect that STAAR Surgical will post -0.03 earnings per share for the current year.
Insider Transactions at STAAR Surgical
In other news, Director Broadwood Partners, L.P. bought 316,017 shares of the company’s stock in a transaction that occurred on Friday, March 13th. The shares were acquired at an average price of $18.61 per share, with a total value of $5,881,076.37. Following the transaction, the director owned 16,123,842 shares in the company, valued at $300,064,699.62. This represents a 2.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders purchased 670,213 shares of company stock valued at $12,266,249. 39.90% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On STAAR Surgical
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Amalgamated Bank raised its position in STAAR Surgical by 3.6% in the 3rd quarter. Amalgamated Bank now owns 14,609 shares of the medical instruments supplier’s stock valued at $393,000 after buying an additional 514 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its stake in shares of STAAR Surgical by 58.2% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,669 shares of the medical instruments supplier’s stock worth $39,000 after purchasing an additional 614 shares in the last quarter. Invesco Ltd. raised its stake in shares of STAAR Surgical by 0.6% during the 3rd quarter. Invesco Ltd. now owns 150,896 shares of the medical instruments supplier’s stock worth $4,055,000 after purchasing an additional 956 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of STAAR Surgical by 2.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 52,535 shares of the medical instruments supplier’s stock worth $1,214,000 after purchasing an additional 1,234 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of STAAR Surgical by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier’s stock worth $518,000 after purchasing an additional 1,267 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.
STAAR Surgical News Summary
Here are the key news stories impacting STAAR Surgical this week:
- Positive Sentiment: STAAR Surgical beat Q1 earnings and revenue expectations, with the business swinging to a profit and showing strong year-over-year improvement. Staar Surgical (STAA) Tops Q1 Earnings and Revenue Estimates
- Positive Sentiment: Wedbush upgraded STAA to Outperform and lifted its price target to $40, citing improving prospects tied to a China recovery. STAAR Surgical was upgraded by Wedbush
- Positive Sentiment: Mizuho also turned more constructive on the stock with a higher price target, reflecting better earnings momentum and outlook expectations. Mizuho Issues Positive Forecast for STAAR Surgical Stock Price
- Positive Sentiment: Commentary around the earnings call highlighted China strength, cost discipline, and stabilizing inventory as drivers of the turnaround. Staar Surgical Signals Sharp Turnaround Amid China Strength
- Neutral Sentiment: Wells Fargo raised its price target to $25 but kept an Equal Weight rating, signaling some caution despite the recent rally. STAAR Surgical had its price target raised by Wells Fargo
- Negative Sentiment: Some analysts still see limited visibility into STAAR Surgical’s 2026 outlook, and a new risk disclosure added to uncertainty around future performance and valuation. Staar Surgical Faces Heightened Uncertainty
About STAAR Surgical
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.
Further Reading
- Five stocks we like better than STAAR Surgical
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
